MCO-010 Gene Therapy for Retinitis Pigmentosa Receives Regulatory Feedback
HCPLive
JANUARY 18, 2024
Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.
Let's personalize your content